Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Lupin stock price, quote, forecast and news

LUPIN.NS
INE326A01037

Price

2,151.70
Today +/-
-0.22
Today %
-0.93 %
P

Lupin stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Lupin stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Lupin stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Lupin stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Lupin's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Lupin Stock Price History

DateLupin Price
9/20/20242,151.70 undefined
9/19/20242,171.90 undefined
9/18/20242,224.95 undefined
9/17/20242,270.40 undefined
9/16/20242,251.85 undefined
9/13/20242,256.45 undefined
9/12/20242,251.55 undefined
9/11/20242,209.40 undefined
9/10/20242,222.55 undefined
9/9/20242,216.80 undefined
9/6/20242,256.50 undefined
9/5/20242,279.50 undefined
9/4/20242,277.25 undefined
9/3/20242,240.25 undefined
9/2/20242,232.75 undefined
8/30/20242,240.20 undefined
8/29/20242,193.75 undefined
8/28/20242,199.00 undefined
8/27/20242,171.55 undefined
8/26/20242,116.20 undefined

Lupin Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lupin, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lupin from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lupin’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lupin. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lupin’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lupin’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lupin’s growth potential.

Lupin Revenue, EBIT and net profit per share

DateLupin RevenueLupin EBITLupin Net Income
2027e270.84 B undefined44.3 B undefined36.31 B undefined
2026e252.39 B undefined39.83 B undefined34.6 B undefined
2025e227.04 B undefined33.84 B undefined27.96 B undefined
2024200.11 B undefined28.09 B undefined19.14 B undefined
2023166.42 B undefined9.21 B undefined4.3 B undefined
2022164.05 B undefined13.25 B undefined-15.28 B undefined
2021151.63 B undefined16.91 B undefined12.17 B undefined
2020153.75 B undefined14.12 B undefined-2.69 B undefined
2019146.65 B undefined17.25 B undefined6.07 B undefined
2018158.04 B undefined20.65 B undefined2.51 B undefined
2017174.94 B undefined35.99 B undefined25.58 B undefined
2016142.56 B undefined32.38 B undefined22.61 B undefined
2015127.7 B undefined33.13 B undefined24.03 B undefined
2014112.87 B undefined28.45 B undefined18.36 B undefined
201396.41 B undefined20.02 B undefined13.14 B undefined
201270.83 B undefined12.57 B undefined8.68 B undefined
201158.19 B undefined10.17 B undefined8.63 B undefined
201048.71 B undefined8.84 B undefined6.82 B undefined
200938.67 B undefined6.81 B undefined5.02 B undefined
200828.92 B undefined5.88 B undefined4.08 B undefined
200722.13 B undefined4.45 B undefined3.04 B undefined
200617.7 B undefined2.57 B undefined1.7 B undefined
200512.85 B undefined1.23 B undefined897 M undefined

Lupin Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
6.715.048.48.9710.4112.6712.8517.722.1328.9238.6748.7158.1970.8396.41112.87127.7142.56174.94158.04146.65153.75151.63164.06166.42200.11227.04252.39270.84
--24.9166.636.7516.0721.721.4237.7525.0530.6833.7125.9719.4721.7236.1217.0713.1411.6322.72-9.66-7.214.84-1.388.191.4420.2413.4611.177.31
41.1847.1049.5053.7849.6050.8549.8653.3357.8859.7558.5159.5758.8560.5360.7263.7164.5966.2667.9763.6363.2961.3061.0554.3753.7161.84---
2.762.374.164.825.166.446.419.4412.8117.2822.6229.0134.2442.8758.5471.9182.4894.46118.91100.5692.8194.2592.5889.1989.39123.76000
0.780.751.251.591.642.441.232.574.455.886.818.8410.1712.5720.0228.4533.1332.3835.9920.6517.2514.1216.9113.259.2128.0933.8439.8344.3
11.6814.9214.8517.6915.7619.249.5914.5120.1020.3317.6118.1417.4717.7520.7725.2125.9422.7220.5713.0611.769.1811.158.075.5314.0414.9115.7816.36
0.250.30.590.710.740.870.91.73.044.085.026.828.638.6813.1418.3624.0322.6125.582.516.07-2.6912.17-15.284.319.1427.9634.636.31
-19.4495.3520.923.9417.463.3488.9679.0634.5322.8335.9126.560.5951.4639.7430.86-5.9313.13-90.17141.38-144.41-551.56-225.61-128.14345.2146.0323.774.95
-----------------------------
-----------------------------
311311403402401401402402403410416438448448449450452453453453454453455.24454.04456.95457.23000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Lupin Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lupin is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                   
0.130.130.150.20.190.30.274.773.850.690.772.014.184.014.339.72218.0527.9616.3630.947.8541.1119.1217.1820.35
1.992.0333.264.222.282.553.114.047.440.590.260.1117.821.8724.6426.4845.4943.0751.9251.554.4644.7442.6244.8146.92
1.71.912.332.523.0521.7522.452.2310.9314.7215.273.983.774.130.26.328.711.9612.3310.169.7313.2112.1712.35
1.51.561.461.431.62.312.623.434.37.899.579.721217.3320.2421.8725.7734.2137.5537.5139.4236.842.7948.2746.6152
0000000002.190.441.050.610.311.220.654.64.812.254.354.394.871.491.353.752.86
5.325.636.957.419.066.897.1913.3114.6320.4422.3127.7632.1743.4251.4361.0178.0498.87119.53122.1138.54154.13139.86124.58124.51134.48
2.842.874.244.4855.326.276.667.9111.0914.117.7120.3124.4926.6328.8831.4743.353.5158.6459.351.2452.3453.9755.454.94
0.340.340.120.10.040.030.030.030.030.060.220.260.030.030.020.020.060.140.220.271.860.360.781.550.772.28
0000000000000.010.773.613.260.631.169.513.874.454.793.4155.412.72
0.130.130.130.1300.060.060.060.060.030.161.741.632.241.361.141.4948.2455.0546.4844.1619.0317.510.0718.3518.32
0000000001.883.173.23.545.215.126.5816.2522.6523.124.4923.818.5219.6221.2422.1923.25
0.290.32000000.020.080.20.220.23.563.670.971.184.6711.875.167.227.391.782.581.812.933.99
3.613.664.494.725.045.416.356.768.0813.2617.8723.129.0736.437.7141.0654.57127.37146.54140.96140.9695.7196.2493.64105.05105.5
8.939.2911.4412.1314.112.313.5420.0822.7133.740.1750.8661.2579.8289.14102.06132.61226.25266.07263.06279.49249.84236.1218.21229.56239.97
                                                   
341386521471401401401401803821828889892893895897899901903904905906907.4909910911.4
0.460.450.450.450.450.450.450.40.411.361.735.065.25.255.385.636.046.787.558.138.649.189.8910.6211.0811.79
1.812.032.632.472.893.434.035.437.5110.6314.4119.7526.6733.5744.9360.8583.32102.82124.34122.81126.22119.77129.37110.73113.3130.69
00000.010.010-00-0.02-2.72-0.020.050.420.841.941.471.182.54.231.98-3.88-1.47-0.72-0.64-0.49
132125009999900000000-49-318-306-329-607-659.5000
2.742.993.613.393.764.314.896.238.7312.814.2525.6832.8140.1352.0469.3291.73111.63134.98135.77137.42125.37138.03121.53124.65142.9
0.791.231.351.382.062.262.663.13.475.647.18.842.2413.7915.4315.9417.8819.8925.8925.7524.9824.1220.1422.8325.3229.58
000.10.10.080.040.040.020.020.040.050.050.010.020.020.021.684.163.432.912.922.982.763.123.434.19
0.140.190.20.140.630.790.430.510.731.785.013.0111.325.337.336.2910.738.538.7115.1114.8619.0612.9218.8720.6323.58
000000000000010.477.274.023.6917.4523.044.5215.824.9330.4937.0242.1726.7
00000.010.010.01000008.631.590.030.030.660.580.142.672.7421.1718.050.921.110.97
0.931.411.661.622.773.093.133.624.227.4712.1611.8922.231.230.0726.334.6350.6161.2150.9661.392.2584.3682.7692.6585.02
5.264.886.176.286.683.954.579.258.6512.0312.2311.42.994.332.471.511.0253.7456.4864.2566.4220.162.753.642.141.55
0000.830.90.940.940.961.11.311.391.631.791.912.342.491.533.273.952.862.8822.32.412.292.46
0000000000000.931.531.631.783.466.689.128.83119.628.127.187.047.21
5.264.886.177.117.574.895.5110.219.7513.3413.6213.035.727.776.435.78663.6869.5575.9380.331.7813.1613.2311.4811.22
6.196.37.838.7310.357.988.6413.8313.9720.8125.7824.9227.9238.9736.532.0840.64114.3130.75126.88141.6124.0397.5295.99104.1396.24
8.939.2911.4312.1314.1112.2913.5320.0622.7133.640.0350.660.7379.188.55101.39132.37225.93265.73262.65279.03249.39235.55217.53228.78239.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lupin provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lupin's financial health and stability.

Assets

Lupin's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lupin must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lupin after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lupin's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.270.350.650.960.991.910.952.264.085.46.068.369.9411.9619.2528.3234.1533.2935.435.4714.097.5716.76-13.727.16
0.120.090.190.230.260.30.340.410.470.650.881.241.712.283.322.614.354.879.1210.8610.8511.68.8716.598.81
0000000000000000000000000
-1.1-0.39-1.36-1.1-0.951.17-0.36-1.66-2.79-3.68-2.76-3.06-3.88-8.73-10.93-12.31-10.18-41.04-6.44-15.78-14.4-9.82-9.080.320.83
0.60.490.630.670.660.530.290.310.030.210.560.20.360.310.871.5-0.780.983.0316.966.125.341.660.492.17
0.510.350.60.630.680.570.290.330.370.360.50.380.330.380.420.280.110.591.512.042.83.561.321.242.27
0.110.090.180.090.32-0.010.170.390.771.091.071.672.443.145.447.729.4411.711.495.589.395.117.16-0.472.43
-0.110.550.10.770.963.911.211.321.782.594.746.748.145.8112.5120.1127.53-1.941.1417.5116.6614.6918.223.6718.97
-193-140-711-558-613-837-1,292-831-1,773-2,347-3,399-6,709-4,287-5,099-5,511-5,286-8,712-58,217-26,368-15,534-9,854-6,731-6,776-9,050-14,996
-0.41-0.13-0.5-0.51-0.6-0.8-1.28-0.77-1.59-4.56-5.1-6.8-5.2-7.41-5.22-8.59-10.55-69.62-25.274.7-32.8311.07-12.412.92-12.87
-0.210.010.210.050.020.030.010.060.19-2.21-1.7-0.09-0.91-2.310.29-3.3-1.83-11.41.0920.23-22.9717.8-5.6221.972.13
0000000000000000000000000
0.55-0.380.50.11-0.29-2.730.624.68-0.461.63-0.252.903.07-4.65-5.3-0.762.089.48-8.9512.92-2.67-14.92-11.690.7
234545-50-700001123312223292111111
0.51-0.420.4-0.21-0.46-30.043.96-1.110.82-1.671.36-1.631.09-6.63-8.57-1.9758.364.33-14.927.44-8.91-18.85-15.72-3.37
-6-9-19-260-69-326-458-391-399-586-456-403-563-551-6073-677-1,772-2,585-3,233-3,968-1,212-1,080-2,248
-61-84-124-248-108-200-260-261-261-407-841-1,081-1,227-1,416-1,434-3,215-1,345-3,368-3,378-3,383-2,248-2,265-2,723-2,950-1,825
-0.01-0-00.04-0.10.11-0.034.5-0.92-1.15-2.031.31.32-0.510.662.9615.02-13.1520.197.29-8.7216.85-13.030.872.73
-305409-6082103473,073-7948462381,343313,8507136,99914,82718,820-60,11214,7671,9786,8067,95711,441.4-5,377.73,976.2
0000000000000000000000000

Lupin stock margins

The Lupin margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lupin. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lupin.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lupin's sales revenue. A higher gross margin percentage indicates that the Lupin retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lupin's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lupin's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lupin's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lupin. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lupin's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lupin Margin History

Lupin Gross marginLupin Profit marginLupin EBIT marginLupin Profit margin
2027e61.84 %16.36 %13.41 %
2026e61.84 %15.78 %13.71 %
2025e61.84 %14.91 %12.31 %
202461.84 %14.04 %9.57 %
202353.71 %5.53 %2.58 %
202254.37 %8.07 %-9.31 %
202161.06 %11.15 %8.02 %
202061.3 %9.18 %-1.75 %
201963.29 %11.76 %4.14 %
201863.63 %13.06 %1.59 %
201767.97 %20.57 %14.62 %
201666.26 %22.72 %15.86 %
201564.59 %25.94 %18.82 %
201463.71 %25.21 %16.27 %
201360.72 %20.77 %13.63 %
201260.53 %17.75 %12.25 %
201158.85 %17.47 %14.82 %
201059.57 %18.14 %13.99 %
200958.51 %17.61 %12.97 %
200859.75 %20.33 %14.12 %
200757.88 %20.1 %13.72 %
200653.33 %14.51 %9.58 %
200549.86 %9.59 %6.98 %

Lupin Stock Sales Revenue, EBIT, Earnings per Share

The Lupin earnings per share therefore indicates how much revenue Lupin has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lupin earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lupin's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lupin’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lupin's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lupin Revenue, EBIT and net profit per share

DateLupin Sales per ShareLupin EBIT per shareLupin Earnings per Share
2027e593.78 undefined0 undefined79.61 undefined
2026e553.33 undefined0 undefined75.86 undefined
2025e497.75 undefined0 undefined61.29 undefined
2024437.66 undefined61.44 undefined41.87 undefined
2023364.19 undefined20.16 undefined9.41 undefined
2022361.32 undefined29.17 undefined-33.65 undefined
2021333.08 undefined37.14 undefined26.72 undefined
2020339.4 undefined31.17 undefined-5.95 undefined
2019323.01 undefined37.99 undefined13.36 undefined
2018348.88 undefined45.58 undefined5.55 undefined
2017386.19 undefined79.45 undefined56.46 undefined
2016314.69 undefined71.48 undefined49.91 undefined
2015282.52 undefined73.29 undefined53.17 undefined
2014250.81 undefined63.22 undefined40.81 undefined
2013214.73 undefined44.59 undefined29.27 undefined
2012158.1 undefined28.06 undefined19.37 undefined
2011129.89 undefined22.69 undefined19.25 undefined
2010111.21 undefined20.18 undefined15.56 undefined
200992.95 undefined16.37 undefined12.06 undefined
200870.53 undefined14.34 undefined9.96 undefined
200754.91 undefined11.03 undefined7.53 undefined
200644.02 undefined6.39 undefined4.22 undefined
200531.96 undefined3.06 undefined2.23 undefined

Lupin business model

Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.com.

Lupin SWOT Analysis

Strengths

Strong brand recognition: Lupin Ltd has established a strong brand presence in the pharmaceutical industry, known for its quality products and innovation.

Diversified product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas, reducing dependency on any single product.

Global presence: Lupin Ltd has a strong international presence, with operations in several countries, allowing it to tap into diverse markets and customer segments.

Weaknesses

Dependency on few key markets: While Lupin Ltd has global operations, it heavily relies on a few key markets for significant revenue, which poses a risk in case of market fluctuations or regulatory challenges in those regions.

Limited pipeline of new drugs: The company's pipeline of new drugs under development is relatively limited, which could impact its ability to maintain a competitive edge and drive future growth.

Increasing competition: Lupin Ltd faces intense competition from other pharmaceutical companies, both domestic and international, which may impact its market share and pricing power.

Opportunities

Rising demand for generic drugs: The increasing preference for affordable healthcare and patent expirations in the pharmaceutical industry present an opportunity for Lupin Ltd to expand its generic drug offerings.

Emerging markets: Developing economies are experiencing a surge in healthcare spending, providing Lupin Ltd with growth opportunities in untapped markets.

Innovation and research: Investing in research and development capabilities can help Lupin Ltd develop new drugs and therapies, driving future growth and differentiation.

Threats

Stringent regulatory environment: Compliance with evolving regulations and increasing scrutiny in the pharmaceutical industry poses a threat to Lupin Ltd's operations and profitability.

Patent expirations: The expiration of patents for key drugs may lead to increased competition from generic drug manufacturers, resulting in reduced market share and lower profitability.

Currency exchange risks: As a global company, Lupin Ltd is exposed to currency exchange rate fluctuations, which can impact its financial performance and profitability.

Lupin Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Lupin historical P/E ratio, EBIT, and P/S ratio.

Lupin shares outstanding

The number of shares was Lupin in 2023 — This indicates how many shares 456.947 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lupin earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lupin's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lupin’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lupin's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lupin Stock splits

In Lupin's history, there have been no stock splits.

Lupin dividend history and estimates

In 2023, Lupin paid a dividend amounting to 4 INR. Dividend means that Lupin distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Lupin provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Lupin’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Lupin's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Lupin Dividend History

DateLupin Dividend
2027e7.39 undefined
2026e7.42 undefined
2025e7.37 undefined
20248 undefined
20234 undefined
20224 undefined
20216.5 undefined
20206 undefined
20195 undefined
20185 undefined
20177.5 undefined
20167.5 undefined
20157.5 undefined
20146 undefined
20134 undefined
20123.2 undefined
20113 undefined
20102.7 undefined
20092.5 undefined
20081 undefined
20071 undefined
20060.65 undefined
20050.65 undefined

Lupin dividend payout ratio

In 2023, Lupin had a payout ratio of 50.67%. The payout ratio indicates the percentage of the company's profits that Lupin distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Lupin represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Lupin could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Lupin's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Lupin Payout Ratio History

DateLupin Payout ratio
2027e38.95 %
2026e41.88 %
2025e37.49 %
202437.47 %
202350.67 %
2022-11.89 %
202124.32 %
2020-101.01 %
201937.43 %
201890.25 %
201713.28 %
201615.03 %
201514.11 %
201414.71 %
201313.67 %
201216.53 %
201115.58 %
201017.35 %
200920.76 %
200810.04 %
200713.3 %
200615.44 %
200529.15 %
Unfortunately, there are currently no price targets and forecasts available for Lupin.

Lupin latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202413.05 17.52  (34.29 %)2025 Q1
3/31/202411.13 7.86  (-29.39 %)2024 Q4
12/31/20239.99 13.41  (34.22 %)2024 Q3
9/30/20237.66 10.72  (39.95 %)2024 Q2
6/30/20236.51 9.9  (52.08 %)2024 Q1
3/31/20233.76 5.16  (37.06 %)2023 Q4
12/31/20225.28 3.36  (-36.37 %)2023 Q3
9/30/20223.83 2.85  (-25.5 %)2023 Q2
6/30/20224.27 -1.96  (-145.88 %)2023 Q1
3/31/20225.77 -11.4  (-297.64 %)2022 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Lupin stock

Eulerpool World ESG Rating (EESG©)

90/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

73

Environment

Scope 1 - Direct Emissions
62,142
Scope 2 - Indirect emissions from purchased energy
277,438
Scope 3 - Indirect emissions within the value chain
901,520
Total CO₂ emissions
339,581
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies✅
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lupin list of shareholders

%
Name
Stocks
Change
Date
6.12952 % Life Insurance Corporation of India27,958,990-9,527,62412/31/2023
45.42372 % Lupin Investments Pvt. Ltd.207,194,390012/31/2023
4.61937 % ICICI Prudential Asset Management Co. Ltd.21,070,633-13,0863/31/2024
3.10551 % HDFC Asset Management Co., Ltd.14,165,389413/31/2024
1.87400 % Nippon Life India Asset Management Limited8,547,994-121,8083/31/2024
1.75419 % Mirae Asset Global Investments (India) Pvt. Ltd.8,001,492341,32112/31/2023
1.68880 % The Vanguard Group, Inc.7,703,230-43,0893/31/2024
1.47464 % HDFC Life Insurance Company Limited6,726,385-935,32112/31/2023
1.35952 % BlackRock Institutional Trust Company, N.A.6,201,270201,7403/31/2024
1.22742 % SBI Funds Management Pvt. Ltd.5,598,694392,44312/31/2023
1
2
3
4
5
...
10

Lupin Executives and Management Board

Ms. Vinita Gupta55
Lupin Chief Executive Officer, Executive Director
Compensation 109.2 M
Mr. Ramesh Swaminathan58
Lupin Executive Director, Global Chief Financial Officer, Chief Risk Officer, Head - Corporate Affairs (since 2007)
Compensation 77.37 M
Mr. Nilesh Gupta49
Lupin Managing Director, Executive Director
Compensation 49.6 M
Mr. Naresh Gupta
Lupin President - API Plus and Global TB
Compensation 14.43 M
Mr. Rajvardhan Satam
Lupin Company Secretary
Compensation 8.56 M
1
2
3
4
...
5

Most common questions regarding Lupin

What values and corporate philosophy does Lupin represent?

Lupin Ltd is known for upholding strong values and a robust corporate philosophy. Guided by their core principles, Lupin strives for excellence, integrity, and transparency in all their operations. The company firmly believes in providing high-quality pharmaceutical products that improve the lives of patients globally. With a focus on innovation, Lupin continually invests in research and development to bring cutting-edge healthcare solutions to the market. Dedicated to social responsibility, Lupin actively engages in initiatives for the betterment of society, promoting sustainable development and fostering inclusive growth. Through their unwavering commitment to quality, ethics, and social welfare, Lupin Ltd emerges as an industry leader, delivering value to various stakeholders and ensuring a positive impact on the healthcare sector.

In which countries and regions is Lupin primarily present?

Lupin Ltd, a renowned pharmaceutical company, has a significant global presence. The company primarily operates in various countries and regions, including but not limited to India, United States, Europe, Japan, and South Africa. With its strong foothold in these markets, Lupin Ltd has established itself as a leading player in the pharmaceutical industry.

What significant milestones has the company Lupin achieved?

Lupin Ltd has accomplished several significant milestones throughout its history. One of the major achievements was the company's successful listing on the Bombay Stock Exchange and the National Stock Exchange of India. Lupin also made notable achievements in the global pharmaceutical industry by receiving various regulatory approvals for its high-quality and affordable generic medications. Furthermore, Lupin has expanded its operations globally by establishing a strong presence in key markets like the United States, Europe, Japan, and other emerging markets. These achievements have reinforced Lupin's position as a leading global pharmaceutical company, delivering innovative healthcare solutions to patients worldwide.

What is the history and background of the company Lupin?

Lupin Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1968, Lupin has emerged as a global leader in the pharmaceutical industry. The company's relentless focus on innovation and research has paved the way for groundbreaking drug discoveries and cutting-edge formulations. Lupin operates through various business segments, catering to a wide range of therapeutic areas including cardiovascular, respiratory, central nervous system, and anti-infective. With a strong global presence across multiple countries, Lupin has earned a stellar reputation for delivering affordable and high-quality healthcare solutions. Over the years, Lupin Ltd. has consistently showcased its commitment to improving global health outcomes with its diverse portfolio of pharmaceutical products.

Who are the main competitors of Lupin in the market?

The main competitors of Lupin Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd., and Torrent Pharmaceuticals Ltd.

In which industries is Lupin primarily active?

Lupin Ltd is primarily active in the pharmaceutical industry.

What is the business model of Lupin?

The business model of Lupin Ltd revolves around the pharmaceutical industry. As a leading global pharmaceutical company, Lupin focuses on developing, manufacturing, and marketing a diverse range of generic and branded pharmaceutical products. With a strong emphasis on research and development, Lupin strives to bring innovative solutions and affordable medications to patients worldwide. The company's business model includes a global presence, strategic partnerships, and a commitment to quality and compliance. Lupin Ltd's extensive product portfolio covers various therapeutic areas, including cardiovascular, central nervous system, dermatology, and respiratory, among others, catering to the healthcare needs of millions of people.

What is the P/E ratio of Lupin 2024?

The Lupin P/E ratio is 51.39.

What is the P/S ratio of Lupin 2024?

The Lupin P/S ratio is 4.92.

What is the AlleAktien quality score of Lupin?

The AlleAktien quality score for Lupin is 6/10.

What is the revenue of Lupin 2024?

The Lupin revenue is 200.11 B INR.

How high is the profit of Lupin 2024?

The Lupin profit is 19.14 B INR.

What is the business model of Lupin

Lupin Ltd is a leading pharmaceutical company based in India. The company's business model is based on the production and distribution of pharmaceutical products and generic medications worldwide. Lupin operates in three business segments: generics, branded products, and carbamazepine. The generics segment is the core of Lupin's business model, offering a wide range of cost-effective alternatives to expensive brand-name medications. Lupin also produces branded products, primarily sold in India, including antibiotics, diabetes medications, and hormonal treatments. The carbamazepine segment specializes in the production of antiepileptic drugs and is a significant part of Lupin's business model. The company also emphasizes research and development, investing a significant percentage of its revenue in the development of new drugs. Lupin has established a global distribution network, with subsidiaries in the US, Europe, and Japan, as well as distribution partners in other countries. The company has made strategic acquisitions and mergers to strengthen its presence in different regions, such as the acquisition of Gavis in 2016 to expand its generics business in the US. Overall, Lupin's business model revolves around the production and distribution of pharmaceutical products and generics worldwide, with a strong emphasis on research and development and a global distribution network.

What is the Lupin dividend?

Lupin pays a dividend of 4 INR distributed over payouts per year.

How often does Lupin pay dividends?

The dividend cannot currently be calculated for Lupin or the company does not pay out a dividend.

What is the Lupin ISIN?

The ISIN of Lupin is INE326A01037.

What is the Lupin ticker?

The ticker of Lupin is LUPIN.NS.

How much dividend does Lupin pay?

Over the past 12 months, Lupin paid a dividend of 8 INR . This corresponds to a dividend yield of about 0.37 %. For the coming 12 months, Lupin is expected to pay a dividend of 7.37 INR.

What is the dividend yield of Lupin?

The current dividend yield of Lupin is 0.37 %.

When does Lupin pay dividends?

Lupin pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Lupin?

Lupin paid dividends every year for the past 23 years.

What is the dividend of Lupin?

For the upcoming 12 months, dividends amounting to 7.37 INR are expected. This corresponds to a dividend yield of 0.34 %.

In which sector is Lupin located?

Lupin is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lupin kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lupin from 9/1/2024 amounting to 8 INR, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Lupin pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Lupin in the year 2023?

In the year 2023, Lupin distributed 4 INR as dividends.

In which currency does Lupin pay out the dividend?

The dividends of Lupin are distributed in INR.

All fundamentals about Lupin

Our stock analysis for Lupin Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lupin Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.